Initiating Transdermal Estradiol Therapy in Turner's Syndrome

Summary

This is a multicenter, randomized, controlled, semi-blinded study to compare two low doses of estradiol administered by recently available transdermal patches for the initiation of puberty in Turner syndrome girls 11.5-13.0 years old in conjunction with growth hormone (GH) therapy. The specific hypotheses to be tested are: when combined with growth hormone (GH) treatment, low dose transdermal estradiol (LTE2) replacement will be more effective in stimulating feminization, height velocity, and bone mineral density without compromising growth potential than very low dose transdermal estradiol (VLTE2), which will in turn be superior to GH alone in effects on feminization, height velocity, and bone mineral density.

Timeline

Start

2009-04

Primary completion

2011-03

Completion

2011-03

Outcome

Outcome not reported

Stopped (Enrollment): “Poor accrual”

Drugs

Indications